^(223)Ra对去势抵抗性前列腺癌骨转移疗效的核医学评估研究进展  

Recent progress of nuclear medicine evaluation of curative effect of^(223) Ra dichloride treatment on castration-resistant prostate cancer and bone metastases

作　　者：楼菁菁 李童童 刘兴党 张宏[1] LOU Jingjing;LI Tongtong;LIU Xingdang;ZHANG Hong(Department of Nuclear Medicine,the Second Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Nuclear Medicine,Pudong Hospital,Fudan University,Shanghai 201399,China;Department of Nuclear Medicine,Huashan Hospital,Fudan University,Shanghai 200040,China;School of Medicine,Shanghai University,Shanghai 200444,China)

机构地区：[1]浙江大学医学院附属第二医院核医学科,杭州310009 [2]复旦大学附属浦东医院核医学科,上海201399 [3]复旦大学附属华山医院核医学科,上海200040 [4]上海大学医学院,上海200444

出　　处：《核技术》2021年第12期35-41,共7页Nuclear Techniques

基　　金：国家重点研发计划(No.2017YFC0113300);浦东新区临床特色学科项目(No.PWYts2021-01);复旦大学附属浦东医院院级引进人才科研启动金计划(No.YJYJRC202108、No.YJYJRC202101)资助。

摘　　要：2020年氯化镭(^(223)Ra)注射液(多菲戈;)获中国国家食品药品监督管理总局(China Food and Drug Administration,CFDA)批准用于治疗伴症状性骨转移,且无已知内脏转移的去势抵抗性前列腺癌(Castration?resistant Prostate Cancer and bone metastases,mCRPC)患者,它是目前世界上第一个应用于mCRPC患者的α粒子靶向放射活性治疗药物。近年来,国外应用核医学技术评估^(223)Ra治疗mCRPC患者的疗效已经十分普遍,国内仅少数医院刚进入临床应用阶段。为使该药在国内得到规范使用,现将国内外^(223)Ra治疗mCRPC患者的临床核医学评估技术进行分析评述。Radium-223 dichloride(^(223)Ra)(Sofigo),a calcium-mimetic agent that specifically targets bone lesions,was approved in 2020 by China Food and Drug Administration(CFDA)to treat castration-resistant prostate cancer and bone metastases(CRPC)with symptomatic bone metastases and no known visceral metastatic diseases.It is the fisrtαparticles targeted radiopharmaceutical therapeutic drugs in the world to be applied to CRPC with bone metastase(mCRPC)patients.In recent years,the application of nuclear medicine technology to evaluate the efficacy of^(223)Ra in the treatment of mCRPC patients abroad has been very common,but only few hospitals in China have entered the stage of clinical application.In order to provide clear recommendations for clinical applications of radionuclide imaging in evaluating the efficacy of^(223)Ra in the treatment of mCRPC,a survey of recent progress is carried out in this study,and public available clinical data of single photon emission computed tomography/computed tomography(SPECT/CT),and positron emission tomography/computed tomography(PET/CT)using radiolabeled chemical agents worldwide in the evaluation of^(223)Ra treatment for patients with CRPC and bone metastase,are presented and commented.

关 键 词：氯化镭(^(223)Ra) 去势抵抗性前列腺癌 单光子发射计算机断层成像术 正电子发射断层成像术 

分 类 号：TL99[核科学技术—核技术及应用]